These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 32361664)

  • 21. Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study.
    Papais-Alvarenga RM; Vasconcelos CC; Carra A; de Castillo IS; Florentin S; Diaz de Bedoya FH; Mandler R; de Siervi LC; Pimentel ML; Alvarenga MP; Alvarenga MP; Grzesiuk AK; Gama Pereira AB; Gomes Neto AP; Velasquez C; Soublette C; Fleitas CV; Diniz DS; Armas E; Batista E; Hernandez F; Pereira FF; Siqueira HH; Cabeça H; Sanchez J; Brooks JB; Gonçalves MV; Barroso MC; Ravelo ME; Castillo MC; Ferreira ML; Rocha MS; Parolin MK; Molina O; Marinho PB; Christo PP; Brant de Souza R; Pessanha Neto S; Camargo SM; Machado SC; Neri VC; Fragoso YD; Alvarenga H; Thuler LC
    PLoS One; 2015; 10(7):e0127757. PubMed ID: 26222205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
    Pache F; Zimmermann H; Mikolajczak J; Schumacher S; Lacheta A; Oertel FC; Bellmann-Strobl J; Jarius S; Wildemann B; Reindl M; Waldman A; Soelberg K; Asgari N; Ringelstein M; Aktas O; Gross N; Buttmann M; Ach T; Ruprecht K; Paul F; Brandt AU;
    J Neuroinflammation; 2016 Nov; 13(1):282. PubMed ID: 27802824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?
    Papais-Alvarenga RM; Neri VC; de Araújo E Araújo ACR; da Silva EB; Alvarenga MP; Pereira ABCNDG; Brandão AC; Alvarenga-Filho H; Guimarães MPM; Marignier R; Barros PO; Bento CM; Vasconcelos CCF
    Mult Scler Relat Disord; 2018 Oct; 25():87-94. PubMed ID: 30056361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
    Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
    Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders.
    Kira J
    J Neurol Sci; 2011 Dec; 311(1-2):69-77. PubMed ID: 21962794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.
    Siritho S; Nakashima I; Takahashi T; Fujihara K; Prayoonwiwat N
    Neurology; 2011 Aug; 77(9):827-34. PubMed ID: 21813785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
    Sato DK; Callegaro D; Lana-Peixoto MA; Waters PJ; de Haidar Jorge FM; Takahashi T; Nakashima I; Apostolos-Pereira SL; Talim N; Simm RF; Lino AM; Misu T; Leite MI; Aoki M; Fujihara K
    Neurology; 2014 Feb; 82(6):474-81. PubMed ID: 24415568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China.
    Yang CS; Zhang DQ; Wang JH; Jin WN; Li MS; Liu J; Zhang CJ; Li T; Shi FD; Yang L
    CNS Neurosci Ther; 2014 Jan; 20(1):32-9. PubMed ID: 23890015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica.
    Yang Y; Huang DH; Wu WP; Wu L; Chen LF; Wu Q
    J Clin Neurosci; 2013 Jan; 20(1):94-8. PubMed ID: 23142234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
    Yang Y; Wu WP; Huang DH; Wu L
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
    Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
    Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
    J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].
    Misu T; Fujihara K; Itoyama Y
    Brain Nerve; 2008 May; 60(5):527-37. PubMed ID: 18516975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions.
    Tanaka K; Tani T; Tanaka M; Saida T; Idezuka J; Yamazaki M; Tsujita M; Nakada T; Sakimura K; Nishizawa M
    Mult Scler; 2007 Aug; 13(7):850-5. PubMed ID: 17468440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.